Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07060547 · ClinicalTrials.gov registry record
Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease
A clinical trial of Alcoholic Hepatitis and Alcohol-related Liver Disease, sponsored by HepQuant.
- Recruiting
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT07060547: Recruiting study of Alcoholic Hepatitis and Alcohol-related Liver Disease, sponsored by HepQuant.
NCT07060547 is a study of Alcoholic Hepatitis and Alcohol-related Liver Disease that is actively recruiting participants, run by HepQuant. The registered enrollment target is 40 participants, below the 293-participant average among 5 other Alcoholic Hepatitis trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07060547, a study of Alcoholic Hepatitis and Alcohol-related Liver Disease, is actively recruiting participants, sponsored by HepQuant.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data to better monitor and treat patients who have been affected by alcohol-associated liver disease. The study has 4 visits at an outpatient clinic at 1, 3, 6, and 12 months. At each of these visits, participants will undergo a HepQuant DuO test and other standard tests. In addition, the study team will ask about a participant's alcohol use, symptoms, and quality of life.
Primary Outcome
The objective of use of the HepQuant DuO test in this study is to evaluate how the HepQuant Disease Severity Index (DSI) changes over time in patients with alcohol-related liver disease (ALD) and to define the relationships of change in HepQuant DSI (ΔDSI) to the changes in the standard of care laboratory and imaging tests used for measuring severity of liver disease and clinical outcomes. The HepQuant DSI is a value on a scale of 0 to 50, where 0 indicates no liver disease and 50 indicates seve
Conditions Studied
Interventions
- DEVICE HepQuant DuO Test
Study Locations (1)
California
- Stanford University Dept. of Medicine -Gastroenterology & Hepatology - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2032-03 |
What NCT07060547 shows while recruiting
NCT07060547 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 293-participant average among 5 other Alcoholic Hepatitis trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Alcoholic Hepatitis appearing as the primary indexed condition, and to 1 intervention - of which HepQuant DuO Test is the first listed.
NCT07060547 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07060547 about?
NCT07060547 is a clinical study titled "Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease". This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes....
What is the current status of trial NCT07060547?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2025-06-10. Estimated completion is 2032-03.
What conditions does trial NCT07060547 study?
This clinical trial studies the following conditions: Alcoholic Hepatitis, Alcohol-related Liver Disease.
What interventions are being tested in trial NCT07060547?
The interventions under investigation include: HepQuant DuO Test (DEVICE).
Who is sponsoring clinical trial NCT07060547?
This trial is sponsored by HepQuant, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07060547 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholic Hepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
RECRUITING · NA
-
Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis
RECRUITING · Phase 1
-
Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
RECRUITING
-
HA35 Moderate Alcoholic Hepatitis (AH) Study
RECRUITING · Early Phase 1
-
Alcoholic Hepatitis Network Observational Study
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI